GSK has agreed to acquire Nuvalent, a Boston‑based clinical‑stage oncology company, for $10.6 billion in cash, in its largest deal in more than a decade. The deal values Nuvalent at $124 per share, a 40% premium to its last closing price of $88.49. GSK will launch a tender offer within 10 business days to acquire all outstanding shares of Nuvalent on the Nasdaq (ticker: NUVL). The transaction is structured to close in Q3 2026, subject to regulatory and customary closing conditions. GSK will pay an aggregate equity value of $10.6 billion ($9.4 billion net of cash), funded primarily through debt and existing cash. Sources: GSK) plans $10.6B Nuvalent acquisition to expand in lung cancer LONDON BRIEFING: GSK agrees to buy US cancer drug maker ... NUVL Jumps As GSK Takeover Talks And FDA Wins Ignite ... GSK to buy US lung cancer drug specialist Nuvalent for £8bn GSK to Acquire Nuvalent for $10.6 Billion in Lung Cancer ... [PDF] Stock-exchange announcement - GSK GSK...
- Get link
- X
- Other Apps